Patient
SITE002-0071
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE002 (USA) (Dr. Nolan)
consented 2025-11-23
Adverse events
6
Serious AEs
0
Open data queries
1
Luna dropout signal
—
not on Luna
Adverse events 6
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 230); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 210); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 195); relationship: NOT RELATED
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-10 (study day 70); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 5); relationship: RELATED
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-06-03 (study day 2); relationship: not assessed
Data queries 1
AE Fatigue (grade 1) for SITE002-0071 has onset 2025-12-08, 1 d before first dose on 2025-12-09. Confirm onset date or record as pre-treatment.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.